Home > Insider Trading > Filing (0001567619-21-021329)

Filing Details

Accession Number:: 0001567619-21-021329
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-11-30 18:07:58
Reporting Period:: 2021-03-31

Accepted Time:: 2021-11-30 18:07:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1811063	Nuvation Bio Inc.	NUVB	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1454385	Oleg Nodelman	357 Tehama Street #3 San Francisco CA 94103	Yes	No	No	No
1567938	Ecor1 Capital Fund, L.p.	357 Tehama Street #3 San Francisco CA 94103	No	No	No	Yes
1587114	Ecor1 Capital, Llc	357 Tehama Street #3 San Francisco CA 94103	No	No	No	Yes
1598292	Ecor1 Capital Fund Qualified, L.p.	357 Tehama Street #3 San Francisco CA 94103	No	No	No	Yes
1778011	Ecor1 Venture Opportunity Fund, Lp	357 Tehama Street #3 San Francisco CA 94103	No	No	No	Yes
1816370	Biotech Opportunity Gp, Llc	1370 Trancas Street, Suite 176 Napa CA 94558	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Stock	Acquisiton	2021-03-31	151,544	$10.45	6,735,790	No	4	P	Indirect	See Notes 2 and 3
Class A Common Stock	Acquisiton	2021-03-31	151,544	$10.45	1,145,600	No	4	S	Indirect	See Notes 2 and 4
Class A Common Stock	Acquisiton	2021-07-31	56,598	$8.64	7,198,407	No	4	P	Indirect	See Notes 2 and 3
Class A Common Stock	Disposition	2021-07-31	56,598	$8.64	1,147,483	No	4	S	Indirect	See Notes 2 and 4
Class A Common Stock	Acquisiton	2021-11-24	163,268	$7.69	7,361,675	No	4	P	Indirect	See Notes 2 and 3
Class A Common Stock	Acquisiton	2021-11-24	21,758	$7.69	1,169,241	No	4	P	Indirect	See Notes 2 and 4

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Notes 2 and 3
No	4	S	Indirect	See Notes 2 and 4
No	4	P	Indirect	See Notes 2 and 3
No	4	S	Indirect	See Notes 2 and 4
No	4	P	Indirect	See Notes 2 and 3
No	4	P	Indirect	See Notes 2 and 4

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	3,165,000	Indirect	See Notes 2 and 5
Class A Common Stock	2,200,627	Indirect	See Notes 2 and 6

Footnotes

EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds.
EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Qualified Fund is the record holder of these securities.
Capital Fund is the record holder of these securities.
EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, Capital Fund, Qualified Fund and Venture Fund. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC, but each Reporting Person disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
These securities are held of record by Venture Fund. Biotech indirectly beneficially owns these securities as the general partner of Venture Fund, and Mr. Nodelman indirectly beneficially owns these securities as the control person of Biotech and EcoR1.